Salvacyl: new treatment for male sexual deviation

Salvacyl (triptorelin) is a new long-acting treatment for men with severe sexual deviations.

It is administered every 12 weeks as a single 11.25mg intramuscular injection.

Triptorelin is a GnRH agonist. It lessens sexual drive by inhibiting secretion of LH and FSH, thereby reducing testosterone production. Other preparations of triptorelin are used to treat precocious puberty, endometriosis and prostate cancer.

Treatment with Salvacyl should be initiated and monitored by a psychiatrist, and must be given in combination with psychotherapy.

View Salvacyl drug record

Further information: Ipsen

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases